Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | TYK2 | P29597 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 4/20 | 0.32 |
| ▸ | RAF1 | P04049 | 3/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128790 | 0.94 | SCN9A (0.35) | JAK2TYK2SCN9AIRAK1IRAK4 | |
| SCHEMBL1339089 | 0.92 | SCN9A (0.35) | SCN9AIRAK1IRAK4BRAFRAF1 | |
| SCHEMBL1338735 | 0.92 | SCN9A (0.35) | SCN9AIRAK1IRAK4BRAFRAF1 | |
| SCHEMBL1339001 | 0.92 | SCN9A (0.37) | JAK2TYK2SCN9AIRAK1IRAK4 | |
| SCHEMBL1339273 | 0.91 | SCN9A (0.36) | SCN9AIRAK1IRAK4BRAFRAF1 | |
| SCHEMBL1338773 | 0.90 | SCN9A (0.35) | SCN9AIRAK1IRAK4BRAFRAF1 | |
| SCHEMBL394212 | 0.89 | SCN9A (0.38) | JAK2TYK2SCN9AIRAK1IRAK4 | |
| SCHEMBL392585 | 0.89 | SCN9A (0.39) | JAK2TYK2SCN9AIRAK1IRAK4 | |
| SCHEMBL1337981 | 0.89 | SCN9A (0.37) | JAK2TYK2SCN9AIRAK1IRAK4 | |
| SCHEMBL4435734 | 0.88 | SCN9A (0.37) | JAK2TYK2SCN9AIRAK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063212-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | claimed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | claimed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | claimed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | JAK2 1281/4885TYK2 2378/4885SCN9A 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.